Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims were evaluated as absent from the provided label sections; the AI did not introduce unsafe or label-contradictory safety/dosing information and appropriately indicated the label does not specify adolescent/total clinical-trial age ranges within the supplied text.
Category Scores
Accurate Statements
The provided label sections shown (including 8.4 Pediatric Use and 8.5 Geriatric Use) do not state a total clinical-trial participant age range (e.g., 17 to 88) within the supplied text.
8.4 Pediatric Use: “Safety and effectiveness… have not been established in pediatric patients.” 8.5 Geriatric Use provides ≥65 breakdown but does not provide an explicit overall participant age range; no total age-range statement appears in the provided sections.
The provided label sections shown do not mention adolescent/late adolescence enrollment or participant ages in that range.
8.4 Pediatric Use states pediatric safety/effectiveness not established but does not describe adolescent/late-adolescence enrollment or ages; 8.5 Geriatric Use discusses ≥65 patients only.
Unsupported Statements
Clinical trial materials list participant ages spanning from 17 to 88 years old.
Not supported by the provided label sections (the supplied text does not include an explicit overall age range for clinical-trial participants).
Polivy testing includes at least some participants in late adolescence.
Not supported by the provided label sections (no adolescent/late-adolescence participant-age information is included in the supplied text).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The AI evaluation concerns absence of explicit age-range/adolescent enrollment details in the provided label text and does not assert incorrect contraindications, boxed warnings, dosing, or safety/efficacy statements that would contradict the supplied sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two participant-age/enrollment claims are not supported by the provided label sections.
Suggested Improvement
Limit age-range/adolescent participation statements to what is explicitly present in the label; otherwise, describe only the supported pediatric statement (safety/effectiveness not established in pediatric patients) and the geriatric ≥65 information shown.